Dexmedetomidine vs. Remifentanil Undergoing Cataract Surgery in Geriatrics

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Dexmedetomidine is an α2-adrenergic receptor agonist used for its sympatholytic effect, providing sedation, analgesia, and cardiovascular stabilization in the perioperative period. Remifentanil is a µ opioid agonist with a rapid onset and short duration of action, which is degraded by plasma esterase in tissues. Investigators aimed to compare the effects of dexmedetomidine and remifentanil infusions on sedation quality, side effects, and surgeon's satisfaction in geriatric outpatients who underwent cataract surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Selcuk University
• Collaborator: Hacettepe University
• Treatments: Dexmedetomidine; Remifentanil

Criteria

Inclusion Criteria:

• Patients between the ages of 65-80,

• Who will undergo cataract surgery,

• With the American Society of Anesthesiologists (ASA) score I-III.

Exclusion Criteria:

• Second or third-degree heart block,

• Chronic α2-agonist use,

• Inability to communicate with the patient,

• Uncontrolled systemic disease,

• Allergy to local anesthetics,

• Chronic analgesic or sedative drug use,

• History of alcohol or substance addiction.